معرفی
May Khanna is an Associate Professor in the Department of Pharmacology & Therapeutics at the University of Florida College of Medicine, where she also serves as the inaugural Assistant Dean for Entrepreneurship and Innovation. She leads a research laboratory focused on developing small molecule therapeutics for neurodegenerative diseases such as Alzheimer’s, ALS, and Batten disease. Her work integrates biochemistry, biophysics, and drug discovery, with funding from the NIH, DOD, and ForeBatten Foundation.
- Ph.D., Wayne State University (2001)
- B.S., Wayne State University (1995)
- Former faculty at University of Arizona and New York University
Her research interests include targeting protein-protein and protein-RNA interactions in neurodegenerative disorders, with a strong emphasis on TDP-43 pathology in ALS. She employs techniques like SPR, NMR, and X-ray crystallography to understand molecular interactions and develop novel therapeutics, including pharmacological chaperones and RNA-targeting compounds.
The most recent publications highlight her lab’s work on TDP-43 modulation, HspA5 interactions, MALAT1 targeting, and aptamer development. These studies collectively advance understanding of neurodegeneration and explore innovative therapeutic strategies such as heterobifunctional degraders and allosteric modulators.
Dr. Khanna has received significant research grants but no specific scientific awards are listed in the text. She is deeply committed to mentoring, with many former trainees now in academic or industry positions.
- Co-founded startups: Regenerix, LLC; Eternum Analytics, LLC; RNATeb
- Principal Investigator on NIH, DOD, and Arizona Alzheimer’s Consortium grants
- Leads the UF Innovation to Entrepreneurship (I2E) program
Her lab includes postdoctoral fellows, graduate students, and research scientists, and she actively promotes entrepreneurship among trainees. She collaborates with institutions including NYU, University of Arizona, UNC, Oxford, and Sanford Research.
حوزههای پژوهشی
